Insmed Inc INSM:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 05/02/24 EDT
25.66quote price arrow up+0.07 (+0.27%)
Volume
1,385,006
52 week range
18.08 - 32.00
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close25.66
  • 52 Week High32.00
  • 52 Week High Date12/28/23
  • 52 Week Low18.08
  • 52 Week Low Date05/17/23

Key Stats

  • Market Cap3.812B
  • Shares Out148.56M
  • 10 Day Average Volume2.32M
  • Dividend-
  • Dividend Yield-
  • Beta0.86
  • YTD % Change-17.2

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close25.66
  • 52 Week High32.00
  • 52 Week High Date12/28/23
  • 52 Week Low18.08
  • 52 Week Low Date05/17/23
  • Market Cap3.812B
  • Shares Out148.56M
  • 10 Day Average Volume2.32M
  • Dividend-
  • Dividend Yield-
  • Beta0.86
  • YTD % Change-17.2

RATIOS/PROFITABILITY

  • EPS (TTM)-5.35
  • P/E (TTM)-4.80
  • Fwd P/E (NTM)-5.56
  • EBITDA (TTM)-667.638M
  • ROE (TTM)-1,453.41%
  • Revenue (TTM)305.208M
  • Gross Margin (TTM)78.52%
  • Net Margin (TTM)-245.59%
  • Debt To Equity (MRQ)-357.00%

EVENTS

  • Earnings Date05/09/2024
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Insmed Inc

 

Profile

MORE
Insmed Incorporated is a global biopharmaceutical company. The Company's first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib and TPIP, as well as other early-stage research programs. Brensocatib is...
William Lewis J.D.
Chairman of the Board, Chief Executive Officer
Roger Adsett
Chief Operating Officer
Sara Bonstein
Chief Financial Officer
Address
700 Us Highway 202/206
Bridgewater, NJ
08807
United States

Top Peers

SYMBOLLASTCHG%CHG
AXSM
Axsome Therapeutics Inc
74.19-0.70-0.93%
RARE
Ultragenyx Pharmaceutical Inc
43.20-0.10-0.23%
FOLD
Amicus Therapeutics Inc
10.43UNCHUNCH
IMCR
Immunocore Holdings PLC
59.46+0.41+0.69%
CRSP
CRISPR Therapeutics AG
55.07+1.26+2.34%